Krystal Biotech, Inc.
Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines built on an engineered HSV-1 gene therapy platform. Its first approved product, VYJUVEK, treats dystrophic epidermolysis bullosa and is being commercialized in the U.S., Europe, and Japan, while the company also advances a pipeline of rare-disease and aesthetic skin programs.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved topical gene therapy for dystrophic epidermolysis bullosa sold in the U.S., EU, and Japan.
Clinical-stage product candidates targeting rare and serious diseases beyond DEB.
Preclinical programs under Jeune Aesthetics focused on aesthetic dermatology applications.
Proprietary HSV-1 vector technology, purification processes, assays, and CGMP manufacturing.
Customers
Krystal Biotech sells primarily to patients with dystrophic epidermolysis bullosa through healthcare providers, specialty pharmacies, and distributors, because VYJUVEK is administered in clinical or home-care settings. Outside the U.S. and major European markets, the company relies on specialty distributors to reach patients and support market access. Its pipeline and preclinical programs are not yet commercial products, so current customer demand is concentrated in the rare-disease treatment channel.
Buy VYJUVEK through the care pathway because it is the only approved corrective therapy for DEB and can be used in office or home settings.
Prescribe and administer VYJUVEK for patients with severe dystrophic epidermolysis bullosa and manage ongoing treatment.
Support dispensing, reimbursement approvals, and patient access, which directly affects commercial uptake.
Buy and distribute VYJUVEK in markets outside the U.S., major EU countries, the UK, and Japan.
Not current revenue customers, but important for future pipeline commercialization and expansion into new indications.
Strategy
Krystal Biotech’s strategy is to maximize VYJUVEK adoption in DEB while expanding geographically through direct commercialization in core markets and distributors elsewhere. At the same time, it is using its HSV-1 platform and internal manufacturing base to build a broader pipeline that can reduce dependence on a single product over time. The company also continues to invest in regulatory approvals, market access, and manufacturing scale to support global launches.
VYJUVEK is the company’s main revenue driver, so broader launch execution is central to growth.
A second or third product would reduce concentration risk and extend the platform’s value.
Internal CGMP capacity supports supply reliability, product quality, and margin control.
Geography
Q1/2026The company is headquartered in Pittsburgh, Pennsylvania and operates as a global commercial-stage biotech with in-house manufacturing in the U.S. It launched VYJUVEK in the U.S. in 2023, began launches in Europe and Japan in 2025, and is expanding through specialty distributors in Central and Eastern Europe, the Middle East, and Turkey. Geography matters because commercialization, reimbursement, and regulatory approval are managed market by market, creating different launch timing and execution risk across regions.
Share of the revenue the company reports by geography.
Risks
The company is highly dependent on VYJUVEK, so any slower-than-expected adoption, reimbursement friction, safety issue, or competitive product could materially affect results. International expansion adds regulatory, distributor, and execution risk, while biotech development risk remains high because pipeline programs may fail in clinical testing or never reach approval. As a commercial biotech, it also faces cybersecurity, manufacturing, and variable-consideration revenue recognition risks that can create quarter-to-quarter volatility.
- Dependence on VYJUVEK commercial successImpact: HighLikelihood: Medium
Near-term revenue and future growth are substantially tied to one approved product.
Exposure: Global commercial business
- International regulatory and market access executionImpact: HighLikelihood: Medium
Approval, pricing, and reimbursement differ by country and can delay or limit uptake.
Exposure - Cybersecurity and third-party service disruptionImpact: MediumLikelihood: High
A 2024 incident at a specialty pharmacy provider delayed reimbursement approvals and hurt revenue.
Exposure: Commercial operations and patient access
- Clinical development failureImpact: MediumLikelihood: Medium
Pipeline candidates may not demonstrate efficacy or obtain approval, limiting diversification.
Exposure: Pipeline programs
- Competitive pressure in gene therapy and DEBImpact: MediumLikelihood: Low
Competitors may launch safer, cheaper, or more convenient therapies first.
Exposure: DEB and adjacent rare disease markets
Accounting
Judgemental itemsNet product revenue depends on estimates for rebates, returns, copay support, and discounts.
Impact: Can change reported sales and margins quarter to quarter
U.S., Europe, and Japan launches occur at different times and reimbursement approvals can shift revenue recognition.
Impact: Creates comparability issues across quarters and regions
A significant component of payroll and operating expense for a biotech company.
Impact: Affects reported operating loss and non-cash expense trends
ASTRA and other CGMP investments require ongoing capital spending and later depreciation.
Impact: Influences gross margin, operating expense, and cash flow
Accumulated losses and uncertain future profitability require judgment on tax asset recoverability.
Impact: Can materially affect tax expense and equity
Similar listed companies
Publicly listed companies with a comparable business focus.
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
Benitec Biopharma Inc.
BNTC · Pharmaceutical Preparations
Abeona Therapeutics Inc
ABEO · Pharmaceutical Preparations
Castle Biosciences, Inc
CSTL · Services-Medical Laboratories
Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in…
BioCryst Pharmaceuticals, Inc
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
Edgewise Therapeutics, Inc.
EWTX · Pharmaceutical Preparations
Last updated: 24/09/2026